Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRD7635
- Development stage
- Preclinical
- Lead developer
- Broad Institute
- Modality
- Small Molecules
01
Overview
BRD7635 is a preclinical small molecule cargo receptor complex disruptor developed by the Broad Institute. It specifically binds to Transmembrane emp24 domain-containing protein 9 (TMED9) and disrupts the hetero-oligomeric TMED7/2/9/10 entrapment complex in the early secretory pathway. This complex is responsible for anchoring and sequestering misfolded mutant proteins, such as frameshifted mucin 1 (MUC1-fs), mutant semaphorin 4A (F350C), and mutant rhodopsin (P23H), within the Golgi apparatus. By disrupting this entrapment complex, BRD7635 promotes the lysosomal degradation of these toxic mutant proteins. It is currently in preclinical development for the treatment of proteinopathies, including Mucin 1 kidney disease (MKD), retinitis pigmentosa, and retinal detachment.
02
Targets
TPPP1 (Tubulin polymerization-promoting protein 1)
Beyond the preview
Go deeper on BRD7635.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRD7635.